Derivative exercise or conversion — not an open-market buy.
Traded Nov 19, 2025 · Filed Nov 22, 2025
Roivant Sciences's Reporting person sold $3.03M of Roivant Sciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,030,000
Shares × reported transaction price
9 days after results of Nov 10, 2025, 79 days before results of Feb 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.4% | +1.7% | −2.1% |
| 30 days | +10.8% | +3.2% | +7.6% |
| 90 days | +36.8% | +2.0% | +34.7% |
| 180 days | +46.1% | +12.2% | +33.9% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
A board member of Roivant Sciences sold $620K of Roivant Sciences shares. Nobody planned it ahead of time.
Not classified as an open-market trade.